Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options Before the October 14th Deadline. If you purchased or acquired stock in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 13, 2025 (GLOBE NEW ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options Before the October 14th Deadline. If you purchased or acquired stock in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 10, 2025 (GLOBE NEW ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options Before the October 14th Deadline. If you purchased or acquired stock in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 06, 2025 (GLOBE NEW ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options Before the October 14th Deadline. If you purchased or acquired stock in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 03, 2025 (GLOBE NEW ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options Before the October 14th Deadline. If you purchased or acquired stock in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 29, 2025 (GLOBE NE ...

文章核心观点 - 律师事务所Bragar Eagel & Squire, P.C.宣布，代表在2024年3月29日至2025年6月27日期间购买Unicycive Therapeutics公司证券的投资者，对该公司提起集体诉讼 [8] - 诉讼指控Unicycive公司就其新药申请相关的生产合规准备状态，向投资者做出了虚假和/或误导性陈述，未披露其满足FDA生产合规要求的能力被夸大 [8] - 受FDA审查结果和完全回应函影响，Unicycive公司股价出现两次大幅下跌，累计跌幅显著 [8] 诉讼事件概述 - 集体诉讼已向美国加州北区地方法院提交，投资者申请担任首席原告的截止日期为2025年10月14日 [8] - 诉讼涉及的类别期为2024年3月29日至2025年6月27日 [8] 指控具体内容 - 被告方吹捧了其药物OLC用于治疗透析慢性肾病患者高磷血症的新药申请前景 [8] - 被告方向投资者保证公司已准备好并有能力满足美国FDA的生产合规要求 [8] - 指控称被告方未能披露其满足FDA生产合规要求的能力被夸大 [8] 股价影响事件 - 2025年6月10日，公司公告FDA在其第三方生产供应商处发现cGMP合规缺陷，导致公司股价下跌超过40% [8] - 2025年6月30日，公司公告FDA就OLC新药申请发出完全回应函，再次提及cGMP缺陷，导致公司股价下跌近30%，收盘报每股4.77美元 [8]

公司诉讼事件 - 针对Unicycive Therapeutics公司(NASDAQ: UNCY)的集体诉讼已提起 涵盖2024年3月29日至2025年6月27日期间购入公司证券的投资者 [1] 指控内容 - 公司被指控就药物奥昔碳酸镧(OLC)的新药申请(NDA)准备情况误导投资者 声称其满足FDA生产合规要求的能力被夸大 [2] - 奥昔碳酸镧用于治疗慢性肾病透析患者的高磷血症 [2] 监管事件影响 - 2025年6月10日FDA通报第三方生产商存在cGMP合规缺陷 导致公司股价单日下跌超过40% [3] - 2025年6月30日FDA针对OLC新药申请发出完全回应函 再次提及cGMP合规问题 公司股价当日下跌近30%至每股4.77美元 [3] 公司背景 - Unicycive Therapeutics为临床阶段生物技术公司 专注于在美国开发针对未满足医疗需求的疗法 [1]

NEW YORK, Aug. 27, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and certain officers.  The class action, filed in the United States District Court Northern District of California, and docketed under 25-cv-06923, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Unicycive securities between March 29, 2024 and June ...

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) and certain officers. The class action, filed in the United States District Court Northern District of California, and docketed under 25-cv-06923, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Unicycive securities between March 29, 2024 and J ...

核心观点 - 律师事务所Bragar Eagel & Squire代表投资者对Unicycive Therapeutics提起集体诉讼 指控公司在2024年3月29日至2025年6月27日期间就药物申请和生产合规问题存在虚假陈述 导致股价两次大幅下跌[8] 诉讼背景 - 集体诉讼针对Unicycive Therapeutics在纳斯达克上市公司 由美国加州北部地区法院受理 涵盖2024年3月29日至2025年6月27日期间购买公司证券的投资者[8] - 投资者需在2025年10月14日前向法院申请成为首席原告[8] 指控内容 - 公司被指控夸大其满足FDA生产合规要求的能力 specifically regarding its New Drug Application for oxylanthanum carbonate (OLC)用于治疗透析慢性肾病患者的高磷血症[8] - 公司未能披露其满足FDA生产合规要求的准备和能力被夸大[8] 股价影响事件 - 2025年6月10日公司公告FDA在第三方制造供应商发现cGMP合规缺陷 导致股价下跌超过40%[8] - 2025年6月30日公司收到FDA就OLC新药申请的Complete Response Letter 再次提及cGMP缺陷 导致股价下跌近30% 收盘价每股4.77美元[8] 投资者参与方式 - 受影响投资者可通过电话(212) 355-4648或邮箱investigations@bespc.com联系律师事务所Brandon Walker或Marion Passmore[1][4] - 参与诉讼无成本或义务[4]